Trial · NCT02568124
Tranexamic Acid in Chronic Subdural Hematomas
NCT02568124, Phase 2, Phase 3, Unknown, Centre de recherche du Centre hospitalier universitaire de Sherbrooke
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Tranexamic Acid in Chronic Subdural Hematomas. Trials, record NCT02568124. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02568124
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tranexamic Acid in Chronic Subdural Hematomas
- NCT number
- NCT02568124
- Status
- Unknown
- Phases
- Phase 2, Phase 3
- Enrollment
- 130 participants, estimated
- Lead sponsor
- Centre de recherche du Centre hospitalier universitaire de Sherbrooke
- Conditions
- Chronic Subdural Hematoma
- Interventions
- Tranexamic Acid, Placebo
- First posted
- 2015-10-05
- Last updated
- 2023-09-05
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hematoma resolution | 20 weeks | The rate of chronic subdural hematoma resolution without intervening unplanned surgical procedure. Specifically, if the initial management strategy chosen by the attending physician within the first 24 hours of presentation consists of expectant management, any surgical procedure leads to a failure of meeting the primary outcome. On the other hand, if the management strategy chosen by the attending physician within the first 24 hours of presentation included a surgical evacuation of the CSDH, the primary outcome is met if the control CT scan at 20 weeks demonstrates a complete radiological resolution of the CSDH. Should a second surgery be required, the subject will fail to meet the primary outcome even if the CSDH has completely resolved by 20 weeks. |
| Secondary | Hematoma volume | 20 weeks | Measured by segmentation analysis on the 20 weeks CT scan |
| Secondary | Surgical evacuation | 32 weeks | The incidence of surgical evacuation procedures |
| Secondary | Hematoma recurrence | 32 weeks | |
| Secondary | Cognitive function | 10 weeks | Assessed by the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) |
| Secondary | Cognitive function | 32 weeks | Assessed by the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) |
| Secondary | Functional autonomy | 10 weeks | Assessed by the modified Barthel Index (mBI) and Glasgow Outcome Scale Extended (GOSE) |
| Secondary | Functional autonomy | 32 weeks | Assessed by the modified Barthel Index (mBI) and Glasgow Outcome Scale Extended (GOSE) |
| Secondary | Quality of life scores at 10 weeks | 10 weeks | Assessed by the EQ-5D-5L and the Sherbrooke Neuro-oncology Assessment Scale (SNAS) |
| Secondary | Quality of life scores at 32 weeks | 32 weeks | Assessed by the EQ-5D-5L and the Sherbrooke Neuro-oncology Assessment Scale (SNAS) |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 27150916 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02568124
GET https://conductscience.org/api/trials/v1/NCT02568124/registered